Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 3
Submit an article Journal homepage
630
Views
13
CrossRef citations to date
0
Altmetric
Drug Safety Evaluation

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients

Alana DikopfThe University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA+1 773 702 4399; +1 773 834 1798; [email protected]
, PharmD BCOP,
Kevin WoodThe University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA+1 773 702 4399; +1 773 834 1798; [email protected]
, MD &
Ravi SalgiaThe University of Chicago Medicine, University of Chicago Medical Center, 5481 S. Maryland Ave, Chicago, IL 60637, USA+1 773 702 4399; +1 773 834 1798; [email protected]
, MD PhD
Pages 485-493 | Published online: 07 Feb 2015

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Giuseppina Gallucci, Alfredo Tartarone, Lucia Lombardi & Michele Aieta. (2015) When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. Expert Review of Anticancer Therapy 15:7, pages 761-763.
Read now

Articles from other publishers (12)

Shun Lu, Hongming Pan, Lin Wu, Yu Yao, Jianxing He, Yan Wang, Xiuwen Wang, Yong Fang, Zhen Zhou, Xicheng Wang, Xiuyu Cai, Yan Yu, Zhiyong Ma, Xuhong Min, Zhixiong Yang, Lejie Cao, Huaping Yang, Yongqian Shu, Wu Zhuang, Shundong Cang, Jian Fang, Kai Li, Zhuang Yu, Jiuwei Cui, Yang Zhang, Man Li, Xinxuan Wen, Jie Zhang, Weidong Li, Jianhua Shi, Xingxiang Xu, Diansheng Zhong, Tao Wang & Jiajia Zhu. (2023) Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial. Signal Transduction and Targeted Therapy 8:1.
Crossref
Sanjeev A. Francis & Douglas Sawyer. 2023. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 20 35 .
Hong Tao, Zhe Liu, Jing Mu, Fei Gai, Zhan Huang & Liang Shi. (2022) Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. Diagnostic Pathology 17:1.
Crossref
Hongjin Zhai, Shuo Zhang, Maxwell Ampomah-Wireko, Huanhuan Wang, Yaquan Cao, Pu Yang, Yingxue Yang, Firas Obald Arhema Frejat, Lihong Wang, Bingbing Zhao, Changzhong Ren & Chunli Wu. (2022) Pyrazole: An Important Core in Many Marketed and Clinical Drugs. Russian Journal of Bioorganic Chemistry 48:6, pages 1175-1189.
Crossref
Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D. Ross Camidge, Karin Berghoff, Soetkin Vlassak & Paul K. Paik. (2022) Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review. Clinical Lung Cancer 23:3, pages 195-207.
Crossref
Elias Chelala, Sandra Hoyek, Nicolas Arej, Joseph Kattan, Hampig Raphael Kourie, Josette Baakliny & Joelle Antoun. (2019) Ocular and orbital side effects of ALK inhibitors: a review article. Future Oncology 15:16, pages 1939-1945.
Crossref
Qinlian Jiao, Lei Bi, Yidan Ren, Shuliang Song, Qin Wang & Yun-shan Wang. (2018) Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Molecular Cancer 17:1.
Crossref
Shu-Yue Zheng, Wen Shen, Yan-Mei Peng, Hui-Juan Cui, Hua Duan, Yu-Qin Qiu, Qiang Li, Jing-Yi Zhang, Chen-Yao Sun & Xu Zhang. (2018) Treatment of severe rash caused by crizotinib with both traditional Chinese medicine and Western medicine. Medicine 97:48, pages e13088.
Crossref
Qian Zhu, Hao Hu, Feng Jiang, Chang Ying Guo, Xiong Wen Yang, Xi Liu & Yu Kang Kuang. (2017) Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK -positive NSCLC . Oncotarget 8:43, pages 75372-75380.
Crossref
Lan Liu, Jing Wu, Wei Zhao & Mei-Juan Huang. (2017) Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib. Medicine 96:21, pages e6979.
Crossref
Jonathan J. Lee, Daniela Kroshinsky & Mai P. Hoang. (2017) Cutaneous Reactions to Targeted Therapy. The American Journal of Dermatopathology 39:2, pages 67-82.
Crossref
Gaetano Romano. (2015) Tumor markers currently utilized in cancer care. Materials and Methods 5.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.